A Multicenter, Open-label Phase II Study to Evaluate the Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
Latest Information Update: 05 Feb 2026
At a glance
- Drugs LP 005 (Primary)
- Indications Immunological disorders; Kidney disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors LongBio Pharma
Most Recent Events
- 05 Feb 2026 New trial record